Find Funding Opportunities

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Postural Orthostatic Tachycardia Syndrome (POTS) is a debilitating condition that affects between 0.2 and 1% of the US population and may be even more prevalent since the COVID-19 pandemic. The conditionimpairs individuals' ability to participate in routine activities such as working, attending school, exercising and activities of daily life. POTS primarily affects women of child-bearing age, with most studies reporting 80-90% female predominance. While many individuals with POTS report symptoms beginning in adolescence, up to half of all individuals with POTS develop it in adulthood. The impact of POTS across the lifespan has until now not been well studied, and given the female preponderance of the condition there is an unmet need to study how the condition is impacted by events such as menarche, pregnancy and menopause. There is a compelling need to stimulate research focused on improving diagnosis and treatment of POTS. This may include development of biomarkers and diagnostic tools as well as translational studies and mechanistic clinical trials to guide the development of interventions aimed at preventing and curing POTS. This NOSI signals interest in this important area with the goal of stimulating research applications to address these critical needs.

The goal of this concept is to increase the impact of the BRAIN Initiative by targeted dissemination and integration of validated BRAIN Initiative tools to investigators at institutions that historically have not been major recipients of NIH support. This will be accomplished by awards to PIs at resource-limited institutions (RLIs) who pair with BRAIN technologists to facilitate training and adoption of BRAIN Initiative technologies in the recipient laboratories. Goals include two-way knowledge transfer between the PI and BRAIN technologist and to increase the participation of PIs at RLIs in BRAIN Initiative relevant research.

TBD

Expiring this NOFO.

Excellent mentorship and superior training are critical to the development of exceptional future scientists. To recognize the crucial role great mentors play in the development of future leaders in neuroscience, the National Institute of Neurological Disorders and Stroke (NINDS) created the Landis Award for Outstanding Mentorship. Each year, this award provides $100,000.00 (direct costs) to up to five (5) faculty members, who have demonstrated a dedication to outstanding mentorship and training. This funding is intended to help foster the research career development of current or additional students and post-doctorates under the guidance of outstanding mentors. NINDS hopes that this tangible award will impress upon the scientific community as a whole, and faculty and institutional leaders in particular, the high value NINDS places on outstanding training and mentorship. Further, NINDS hopes that it encourages institutions to reward individuals not only for outstanding research accomplishments but also for their impact on the lives of others, and the future of neuroscience, through outstanding mentorship and training.

The purpose of this Notice of Change is to inform current and future recipients of the NINDS R35 Research Program Award (RPA) of a change to the opportunity to request a budget increase based on exceptional circumstances at the year five (5) administrative review.

The purpose of this notice is to inform applicants of the early termination of PAR-22-184 "NINDS/NCATS Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases".

The purpose of this notice of correction is to inform applicants of the removal of the basic science experimental studies (BESH) language from PAR-24-219 NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed). Clinical Trials, including BESH, are not allowed under this notice of funding opportunity (NOFO).

The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH) intend to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) that solicits applications focused on the neurological and psychiatric manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neuropsychiatric mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition).